|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: THEMIS2 |
Gene summary for THEMIS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | THEMIS2 | Gene ID | 9473 |
| Gene name | thymocyte selection associated family member 2 | |
| Gene Alias | C1orf38 | |
| Cytomap | 1p35.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q5TEJ8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9473 | THEMIS2 | male-WTA | Human | Thyroid | PTC | 2.18e-17 | 2.06e-01 | 0.1037 |
| 9473 | THEMIS2 | PTC01 | Human | Thyroid | PTC | 5.36e-03 | 1.01e-01 | 0.1899 |
| 9473 | THEMIS2 | PTC04 | Human | Thyroid | PTC | 2.16e-04 | 1.53e-01 | 0.1927 |
| 9473 | THEMIS2 | PTC05 | Human | Thyroid | PTC | 1.05e-10 | 6.85e-01 | 0.2065 |
| 9473 | THEMIS2 | PTC06 | Human | Thyroid | PTC | 1.87e-19 | 6.09e-01 | 0.2057 |
| 9473 | THEMIS2 | PTC07 | Human | Thyroid | PTC | 3.50e-12 | 2.34e-01 | 0.2044 |
| 9473 | THEMIS2 | ATC09 | Human | Thyroid | ATC | 8.63e-13 | 4.97e-01 | 0.2871 |
| 9473 | THEMIS2 | ATC12 | Human | Thyroid | ATC | 2.06e-02 | 3.58e-02 | 0.34 |
| 9473 | THEMIS2 | ATC1 | Human | Thyroid | ATC | 2.48e-12 | 5.39e-01 | 0.2878 |
| 9473 | THEMIS2 | ATC4 | Human | Thyroid | ATC | 3.66e-07 | 8.83e-02 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005085210 | Thyroid | PTC | T cell receptor signaling pathway | 52/5968 | 123/18723 | 9.58e-03 | 3.93e-02 | 52 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| THEMIS2 | SNV | Missense_Mutation | c.1871N>T | p.Asp624Val | p.D624V | Q5TEJ8 | protein_coding | deleterious(0.04) | benign(0.166) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| THEMIS2 | SNV | Missense_Mutation | novel | c.1618N>T | p.Arg540Trp | p.R540W | Q5TEJ8 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-BH-A8G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| THEMIS2 | insertion | Nonsense_Mutation | novel | c.1113_1114insTGTGGCGTAGTGTAAATTGGAAGATTCTGATTGGAAAGAAAA | p.Gly371_Asp372insCysGlyValValTerIleGlyArgPheTerLeuGluArgLys | p.G371_D372insCGVV*IGRF*LERK | Q5TEJ8 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| THEMIS2 | deletion | Frame_Shift_Del | novel | c.1191delG | p.Leu398Ter | p.L398* | Q5TEJ8 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| THEMIS2 | SNV | Missense_Mutation | novel | c.916N>G | p.Lys306Glu | p.K306E | Q5TEJ8 | protein_coding | deleterious(0) | benign(0.055) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| THEMIS2 | SNV | Missense_Mutation | novel | c.917N>G | p.Lys306Arg | p.K306R | Q5TEJ8 | protein_coding | tolerated(0.2) | benign(0.011) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| THEMIS2 | SNV | Missense_Mutation | c.1552N>A | p.Leu518Met | p.L518M | Q5TEJ8 | protein_coding | tolerated(0.25) | benign(0.028) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| THEMIS2 | SNV | Missense_Mutation | novel | c.1296N>T | p.Glu432Asp | p.E432D | Q5TEJ8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| THEMIS2 | SNV | Missense_Mutation | novel | c.1296N>T | p.Glu432Asp | p.E432D | Q5TEJ8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| THEMIS2 | SNV | Missense_Mutation | novel | c.962N>G | p.Gln321Arg | p.Q321R | Q5TEJ8 | protein_coding | tolerated(0.19) | benign(0.018) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |